These factors may have led to the lower efficacy and safety in the onabotulinumtoxinA group among men with higher PSA levels in our results, although more information is needed (urodynamics, bladder wall thickness, history of urinary tract infections, and cystoscopy outcomes). The gene discussed is KLK3; the disease is urinary tract infection.